Companies: 10,795·Total market cap: $144.5T
Decibel Therapeutics, Inc.

Decibel Therapeutics, Inc.

DBTXNASDAQHealthcare
$4.91
$-0.04(-0.81%)
Market Cap$123373079
P/E Ratio
52W High$5.4
52W Low$1.61

Decibel Therapeutics, Inc. (DBTX) Stock Ownership

Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.

SEC 13F · FMP · DBTX · as of Dec 31, 2023

Ownership Breakdown

Institutions 0.16%
Insiders 46.68%
Public 53.16%

1

Institutional Holders

$36,400

Total Inst. Value

25.13M

Shares Outstanding

freeFloat 53.32%

40,000

13F Shares Held

Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.

Top Institutional Holders

DBTX largest shareholders · institutional ownership

Q4 2023 · SEC 13F

Showing top 1 holders

HolderShares% OwnedWeightValueReportedChange

ATLAS CAPITAL ADVISORS LLC

pharmaceutical preparations

40.0K15.99%

15.99%

$36.40MFeb 15, 2024— held

Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).

Institutional Activity

Q4 2023 vs prior quarter

Q4 2023

0

Increased

+0 shares

0

New Positions

first time holders

0

Decreased

−0 shares

0

Sold Out

fully exited

Net shares change (top 50)

+0

+0 / −0

Net new holders

+0

0 new / 0 exited

Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).

Insider Buying vs Selling

DBTX insider trading · insider activity

Source: SEC Form 4

0

Buy transactions

29

Sell transactions

0.00

Buy/Sell ratio

$3M

Total disposed

Recent Insider Transactions

Showing 10 most recent · Common Stock only

Name · RoleDateTypeSharesPriceValueAfter Trans.Filing

Trask Anna

Chief People Officer

Sep 25, 2023D-Return106,864$3.50$374.0K0Form 4 ↗

Trask Anna

Chief People Officer

Sep 25, 2023D-Return45,000$3.12$140.4K0Form 4 ↗

Trask Anna

Chief People Officer

Sep 25, 2023D-Return52,500$3.50$183.8K0Form 4 ↗

Trask Anna

Chief People Officer

Sep 25, 2023D-Return137,302$4.40$604.1K0Form 4 ↗

Carson William H.

director

Sep 25, 2023D-Return10,000$2.30$23.0K0Form 4 ↗

Carson William H.

director

Sep 25, 2023D-Return5,000$3.50$17.5K0Form 4 ↗

Carson William H.

director

Sep 25, 2023D-Return5,000$4.78$23.9K0Form 4 ↗

Carson William H.

director

Sep 25, 2023D-Return20,000$8.42$168.4K0Form 4 ↗

Lee John Jui-Jen

Chief Development Officer

Sep 25, 2023D-Return147,144$3.50$515.0K0Form 4 ↗

Lee John Jui-Jen

Chief Development Officer

Sep 25, 2023D-Return45,000$3.12$140.4K0Form 4 ↗

Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.

About institutional & insider ownership

Decibel Therapeutics, Inc. (DBTX) is primarily owned by institutional investors, who hold approximately 0.2% of total shares outstanding. Company insiders own approximately 46.68%, while retail and public investors account for the remaining 53.16%.

The largest institutional shareholder of Decibel Therapeutics, Inc. is ATLAS CAPITAL ADVISORS LLC, holding approximately 40,000 shares — equal to 15.99% of outstanding shares — as of December 31, 2023.

A total of 1 institutional investors currently hold DBTX stock, with a combined institutional value of approximately $36,400 as of the most recent 13F filing period.

Frequently asked questions

DBTX ownership

Decibel Therapeutics, Inc. (DBTX) is primarily owned by institutional investors, who hold approximately 0.2% of shares. The largest shareholder is ATLAS CAPITAL ADVISORS LLC with a 15.99% stake. Company insiders hold 46.68%. Data sourced from SEC Form 13F as of December 31, 2023.

who owns DBTX stockDBTX ownership structureSEC Form 13F institutional holdingsDBTX float vs institutions
Source: FMP · SEC Form 13F · SEC Form 4As of December 31, 2023